Prolactin in combination with interferon-ß reduces disease severity in an animal model of multiple sclerosis.
J Neuroinflammation
; 12: 55, 2015 Mar 19.
Article
in En
| MEDLINE
| ID: mdl-25889599
ABSTRACT
Previous work has demonstrated that the hormone prolactin promotes oligodendrocyte precursor proliferation and remyelination following lysolecithin-induced demyelination of the mouse spinal cord. Prolactin, however, can elicit pro-inflammatory responses, and its use in the prototypical demyelinating and inflammatory condition, multiple sclerosis (MS), should thus be approached cautiously. Here, we sought to determine whether recombinant prolactin could alter the course of experimental autoimmune encephalomyelitis (EAE), an inflammatory animal model of MS. Consistent with previous literature, we found that prolactin activated leukocytes in vitro. Daily treatment with prolactin from around the time of onset of clinical signs, for 9 (days 9 to 17) or 25 (days 9 to 33) days did not increase clinical or histological signs of EAE over that of vehicle-treated mice. Instead, the combination of prolactin and a suboptimal dose of recombinant murine interferon-ß resulted in (days 9 to 17 group) or trended towards (days 9 to 33 group), a greater amelioration of clinical signs of EAE, compared to either treatment alone or to vehicle controls. Histological analyses corroborated the clinical EAE data. These results suggest that prolactin may be beneficial when administered in combination with interferon-ß in MS.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prolactin
/
Interferon-beta
/
Immunologic Factors
/
Multiple Sclerosis
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
J Neuroinflammation
Journal subject:
NEUROLOGIA
Year:
2015
Type:
Article
Affiliation country:
Canada